EMG
ENTA icon

Ellington Management Group’s Enanta Pharmaceuticals ENTA Stock Holding History

Ellington Management Group’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-5,500
Closed -$257K – 655
2017
Q3 		$257K Buy
+5,500
New +$221K 0.04% 446
2015
Q2 		– Sell
-12,100
Closed -$371K – 729
2015
Q1 		$371K Buy
+12,100
New +$471K 0.08% 387
2014
Q1 		– Sell
-11,500
Closed -$314K – 648
2013
Q4 		$314K Buy
+11,500
New +$279K 0.11% 292

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ellington Management Group's ENTA Position: Q4 2017 in Review

Ellington Management Group sold out of Enanta Pharmaceuticals (ENTA) in Q4 2017, closing a stake of 5,500 shares — an estimated $257K sold.

Ellington Management Group first reported a position in ENTA in Q4 2013 and held it in 3 quarters. The position peaked at $371K in Q1 2015. 148 funds tracked by Wall St. Rank hold ENTA as of Q4 2017.

  • Ellington Management Group reported no remaining Enanta Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Ellington Management Group sold 5,500 Enanta Pharmaceuticals shares in Q4 2017, an estimated $257K.
  • Ellington Management Group first reported a position in Enanta Pharmaceuticals in Q4 2013 and held it in 3 quarters.
  • Ellington Management Group's Enanta Pharmaceuticals position peaked at $371K in Q1 2015.
  • 148 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2017.

Based on Ellington Management Group's 13F filing for Q4 2017, filed 14 Feb 2018.